You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥集團:國藥新冠疫苗總年產能達100億劑
阿思達克 08-16 16:08
國藥集團黨委書記、董事長劉敬楨表示,目前國藥疫苗在119個國家地區及國際組織獲準使用,覆蓋196個國別人羣,內地外生產供應超過35億劑。 國藥集團中國生物黨委書記、副總裁朱京津表示,爲了確保疫苗的可及性,國藥集團中國生物先後投入300多億元,建設三個P3級的高等級實驗室,6個P3級的高等級生物安全車間,新冠疫苗總體年產能達100億劑,成爲全球最大新冠疫苗研發生產基地和最大供應商。 朱京津表示,中國生物研發的Omicron變異株滅活疫苗、第二代重組蛋白新冠疫苗均獲得臨牀批件,Omicron變異株mRNA疫苗也已提交臨牀申請。治療藥物新冠特異免疫球蛋白正不斷馳援疫情較重地區,單克隆抗體F61、2B11和DXP604先後進入臨牀試驗,針對新流行猴痘病毒的檢測試劑盒獲得歐盟CE認證。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account